- Home
- UTHR
as 07-08-2024 2:36pm EST
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 12.1B | IPO Year: | 1999 |
| Target Price: | $310.40 | AVG Volume (30 days): | 653.6K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 21.12 | EPS Growth: | 42.41 |
| 52 Week Low/High: | $208.62 - $325.00 | Next Earning Date: | 07-31-2024 |
| Revenue: | $2,498,300,000 | Revenue Growth: | 26.09% |
| Revenue Growth (this year): | 20.09% | Revenue Growth (next year): | 8.16% |
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 28 '24 | Sell | $324.58 | 412 | $133,728.57 | 130 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 28 '24 | Sell | $323.26 | 254 | $82,107.48 | 542 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 28 '24 | Sell | $322.27 | 261 | $84,112.60 | 796 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 28 '24 | Sell | $321.31 | 372 | $119,528.47 | 1,057 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 28 '24 | Sell | $319.61 | 743 | $237,467.11 | 1,429 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 28 '24 | Sell | $318.94 | 1,431 | $456,400.28 | 2,172 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 28 '24 | Sell | $317.09 | 127 | $40,269.88 | 3,603 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 28 '24 | Sell | $320.99 | 715 | $229,510.71 | 130 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 28 '24 | Sell | $319.80 | 655 | $209,466.58 | 845 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 28 '24 | Sell | $318.74 | 744 | $237,139.21 | 1,500 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 28 '24 | Sell | $317.49 | 484 | $153,666.56 | 2,244 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 28 '24 | Sell | $316.41 | 1,002 | $317,041.52 | 2,728 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 24 '24 | Sell | $310.71 | 96 | $29,828.16 | 3,634 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 24 '24 | Sell | $312.75 | 341 | $106,648.50 | 3,293 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 24 '24 | Sell | $313.91 | 591 | $185,523.47 | 2,702 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 24 '24 | Sell | $314.98 | 756 | $238,126.32 | 1,946 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 24 '24 | Sell | $316.57 | 122 | $38,620.95 | 1,824 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 24 '24 | Sell | $317.52 | 935 | $296,884.66 | 889 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 24 '24 | Sell | $318.54 | 637 | $202,908.90 | 252 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 24 '24 | Sell | $319.33 | 122 | $38,958.66 | 130 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 24 '24 | Sell | $318.44 | 697 | $221,950.03 | 3,033 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 24 '24 | Sell | $319.11 | 1,853 | $591,302.86 | 1,180 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 24 '24 | Sell | $320.02 | 886 | $283,541.00 | 294 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 24 '24 | Sell | $321.82 | 164 | $52,778.48 | 130 | SEC Form 4 |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Jun 20 '24 | Sell | $304.93 | 257 | $78,366.83 | 3,473 | SEC Form 4 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
MT Newswires
6 hours ago
UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating
Argus Research
3 days ago
Analyst Report: United Therapeutics Corp
Argus Research
3 days ago
Market Digest: STZ, UTHR, NET
MT Newswires
10 days ago
United Therapeutics Insider Sold Shares Worth $2,395,035, According to a Recent SEC Filing
MT Newswires
10 days ago
United Therapeutics Insider Sold Shares Worth $2,285,941, According to a Recent SEC Filing
FX Empire
10 days ago
Big Money Elevating United Therapeutics
Zacks
11 days ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Business Wire
11 days ago
United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
Share on Social Networks:
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.